Abstract
The purpose of this study was to investigate the association among matrix metalloproteinases (gelatinases A and B, stromelysin-3 (ST3) and matrilysin) mRNAs expressed in primary breast carcinomas and stan-dard prognostic parameters and clinical outcome. mRNA levels were determined by Northern analysis in samples of 81 breast cancer patients (median follow-up, 40 months) and 27 samples of uninvolved adjacent breast tissue. Proteases were expressed by the majority of the tumors and normal breast tissues examined. ST3, gelatinase A and matrilysin mRNAs were more often expressed at high levels in carcinomatous than in normal breast tissues. Differences in the distribution of gelatinase B mRNA were not found. However, paired normal tissues generally produced weaker signals when compared to matched tumor samples. Univariate analysis showed no significant association of gelatinase A and matrilysin mRNAs with the classical prognostic markers (age, menopausal status, stage, size, nodal status, vascular infiltrate, necrosis, steroid receptors, metastasis and survival). Overexpression of ST3 was more frequently found in tumors of post-menopausal women (P < 0.022). Elevated expression of gel B mRNA was associated with the presence of vascular infiltrate (P < 0.026), necrosis (P < 0.039), PR negative tumors (P < 0.014) and inversely corre-lated to the number of survivors (P < 0.021). Multivariate analysis including 68 patients for whom all information was available indicated that neither stromelysin correlated significantly with pathological, clin-ical or biochemical features. High levels of gelatinase A and B mRNAs were inversely associated with the number of survivors. Our findings suggest that measurements of gelatinase A and B mRNAs expression in breast carcinoma may help to identify patients with an agressive form of the disease. ©Lippincott Williams & Wilkins
Similar content being viewed by others
References
Duffy MJ, 1996, Proteases as prognostic markers in cancer. Clin Cancer Res, 2, 613-18.
Wolf C, Rouyer N, Lutz Y et al.,1993, Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA,90, 1843-47.
Monteagudo C, Merino MJ, San-Juan J et al.,1990, Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol, 136, 585-92.
Daidone MG, Silvestrini R, D'Errico A et al.,1991, Laminin receptors, collagenase IV and prognosis in node-negative breast cancer. Int J Cancer, 48, 529-32.
Brown PD, Bloxidge RE, Anderson E and Howell A, 1993, Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Met, 11, 183-9. 11111
Davies B, Miles DW, Happerfield LC et al.,1993, Activity of type IV collagenases in benign and malignant breast tissue disease. Br J Cancer, 67, 1126-31.
Polette M, Gilbert N, Stas I et al.,1994, Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Archiv, 424, 641-5.
Visscher DW, Höyhtyä M, Ottosen SK et al.,1994, Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer, 59, 339-44.
Duffy MJ, Blaser J, Duggan C et al., 1995, Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer, 71, 1025-8.
Lee KS, Rha SY, Kim JH et al., 1996, Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis,14, 512-9.
Chambers AF and Matrisian LM, 1997, Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst, 89, 1260-70.
Rio MC, Lefebvre O, Santavicca M et al., 1996, Stromelysin-3 in the biology of the normal and neo-plastic mammary gland. J Mamm Gland Biol Neo, 1, 231-40.
Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH, 1996, Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol, 149, 273-82.
Hähnel E, Harvey JM, Joyce R et al., 1993, Stromelysin-3 expression in breast cancer biopsies: clinico-pathological correlations. Int J Cancer, 55, 771-4.
Santavicca M, Noël A, Chenard M-P et al., 1995, Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry. Int J Cancer, 64, 336-41.
Basset P, Belloq JP, Wolf C et al., 1990, A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704.
Collier IE, Wilhelm SM and Eisen AZ, 1988, H-ras oncogene-transformed human bronchial ephitelial cells (TBE-1) secrete a single metalloprotease capable of degradating basemant membrane collagen. J Biol Chem, 263, 6579-87.
Wilhelm SM, Collier IE, Marmer BL et al., 1989, SV40-transformed human lung fibroblasts secrete a 92-kDa collagenase which is identical to that secreted by normal human macrophages. J Biol Chem, 264, 17213-21.
Muller D, Quantin B, Geshel MC et al., 1988, The collagenase gene family in humans consistis of a least four members. Biochem J, 253, 187-92.
Arnhein N, 1979, Characterization of mouse ribosomal gene fragments purified by molecular clone. Gene, 72, 83-96.
Chomczynski P and Sacchi N, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extration. Anal Biochem, 162, 156-9.
Fourney RM, Miyashi J, Day III RS and Paterson MC, 1988, Northern blotting: efficient RNA staining and transfer. Focus, 10, 5-7.
Pacheco MM, Brentani MM, Franco EL et al., 1988, Plasminogen activator expression and steroid hormone receptors in female breast cancer: a multi-factorial study. Int J Cancer, 41, 798-804.
Kawami H, Yoshida K, Ohsaki A et al., 1993, Stromelysin-3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res, 13, 2319-24.
Engel G, Heselmeyer K, Auer G et al., 1994, Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer, 58, 830-5.
Chenard M-P, O'Siorain L, Shering S et al., 1996, High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer, 69, 448-51.
Kossakowska AE, Huchcroft SA, Urbanski SJ and Edwards DR, 1996, Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer, 73, 1401-8.
Singer CF, Rasmussen A, Lippman ME and Cullen KJ, 1997, Coexpression of stromelysin-3 and insulin-like growth factor II in tumors of ectodermal, mesodermal, and endodermal origin: Indicator of a fetal cell phenotype. J Clin Endocrinol Metab, 82, 1917-22.
Basset P, Wolf C, Rouyer N et al., 1994, Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer ( Suppl ), 74, 1045-9.
Noël AC, Lefebvre O, Maquoi E et al., 1996, Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest, 97, 1924-30.
Ahmad A, Marshall JF, Basset P et al., 1997, Modulation of human stromelysin 3 promotes activity and gene expression by human breast cancer cells. Int J Cancer, 73, 290-6.
MacDougall JR, Rudolph LA, Arteaga C and Matrisian LM, 1997, Expression of the metalloproteinase matrilysin is regulated by both positive and negative factors in breast cancer cells. Proc Am Assoc Cancer Res, 38, 405.
Onisto M, Riccio MP, Scannapieco P et al., 1995, Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer, 63, 621-6.
Ree AH, Florenes VA, Berg JP et al., 1997, High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res, 3, 1623-28.
Zucker S, Lysik RM, Zarrabi MH and Moll U, 1993, Mr 92,000 types IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res, 53, 140-6.
Soini Y, Hurskainen T, Hoyhtya M et al.,1994, 72 kD and 92 kD type IV collagenase, type IV collagen and laminin mRNAs in breast cancer: a study by in situhybridization. J Histochem Cytochem, 42, 945-51.
Nielsen BS, Sehested M, Kjeldsen L et al., 1997, Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest, 77, 345-55.
Mantovani A, 1994, Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest, 71, 5-16.
Matrisian LM, 1990, Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet, 6, 121-5.
Emonard HP, Ramacle AG, Noel AC et al.,1992, Tumour cell surface-associated binding site for the Mr 72,000 type IV collagenase. Cancer Res, 52, 5845-8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pacheco, M.M., Mourao, M., Mantovani, E.B. et al. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 16, 577–585 (1998). https://doi.org/10.1023/A:1006580415796
Issue Date:
DOI: https://doi.org/10.1023/A:1006580415796